Press Releases

You Narrowed By: Business/Product Release

Showing 1-35 of 173

First 1 2 3 4 5 Next Last

2013
May
May 9	Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes
May 7	New Parenting Survey Reveals That Nearly All Moms Feel Judged on Parenting Decisions

April
April 18	Abbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric Intraocular Lens for Cataract Patients
April 16	Abbott Introduces Next Generation Laboratory Automation Solution to Help Meet Increased Testing Demand
April 15	Abbott Initiates Voluntary Recall of FreeStyle InsuLinx® Blood Glucose Meters in the United States
April 10	Abbott's Galectin-3 Test Provides Doctors in Europe with New Tool for Assessing the Prognosis of Chronic Heart Failure Patient

March
March 28	New Abbott Test Can Help Doctors Detect the Presence of Two Important Health Issues
March 20	FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery
March 11	New Data Reinforce Strong Long-Term Clinical Performance of Abbott's Absorb™ Bioresorbable Vascular Scaffold
March 10	Abbott's Minimally Invasive MitraClip^® System for Mitral Regurgitation Demonstrates Positive Clinical and Quality- of-Life Results for Patients Too High Risk for Surgery
March 4	Abbott Introduces Nutrition for Active Kids - Kidz ZonePerfect® Nutrition Bars

February
February 21	Abbott to Collaborate with Janssen and Pharmacyclics on Development of Companion Test for Investigational Leukemia Therapy
February 12	New Survey Reveals Eight in 10 Fitness Enthusiasts Are Not Doing Enough to Aid Recovery After Exercise

January
January 9	New Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluating Potential Heart Attacks
January 8	Abbott Initiates Clinical Trial of Absorb™ in the United States
January 3	Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System
January 2	Abbott Completes Separation of Research-Based Pharmaceuticals Business
2012
December
December 17	Abbott Announces New Testosterone Test to Measure the Hormone at Low Levels
December 17	AbbVie Inc. Common Stock Approved for Listing on NYSE Euronext Paris
December 13	New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks

November
November 27	Abbott’s HUMIRA® (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn’s Disease
November 13	Abbott Announces Phase 3 Hepatitis C Program Details
November 12	Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
November 12	Abbott Announces Results of Analysis Exploring the Use of HUMIRA® (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis
November 10	Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®

October
October 30	Abbott Introduces Ensure Complete™ Shakes For Adults
October 24	Abbott Announces Data Evaluating Reduction of Steroid Usage with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis
October 24	Abbott’s ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
October 23	Abbott Announces New Data Evaluating Mucosal Healing with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis
October 22	Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA® (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
October 19	Abbott Receives Positive Opinion from CHMP for HUMIRA® Use in Pediatric Crohn's Disease
October 15	Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study

September
September 28	Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis
September 25	Abbott Announces International Launch of the Absorb™ Bioresorbable Vascular Scaffold
September 12	According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives

First 1 2 3 4 5 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.